What is Deepcell?
Founded in 2017, Deepcell is transforming the field of single-cell analysis by combining artificial intelligence with high-throughput cell classification and capture. The company's core technology utilizes microfluidics to sort cells based on detailed visual features without inherent bias, maintaining cell viability for downstream applications. This capability allows researchers to isolate rare cell populations—even those occurring at frequencies as low as one in a billion—providing a powerful tool for translational research, diagnostics, and therapeutic discovery. By removing the limitations of traditional sorting methods, Deepcell is establishing a new standard for precision medicine and biological data acquisition.
How much funding has Deepcell raised?
Deepcell has raised a total of $93M across 2 funding rounds:
Series A
$20M
Series B
$73M
Series A (2020): $20M with participation from Andreessen Horowitz, Jeff Dean, Stanford University, 50Y, Bow Capital, and DCVC
Series B (2022): $73M led by Horizons Ventures, Bridger Healthcare, Koch Disruptive Technologies, and Casdin Capital
Key Investors in Deepcell
DCVC
A deep tech venture capital firm that leverages artificial intelligence to unlock potential across biotechnology and energy sectors, supporting founders who tackle complex global challenges.
Casdin Capital
An investment firm specializing in the life sciences industry, with a focus on financing the next generation of diagnostics and molecular information pioneers.
Bow Capital
A venture capital fund that bridges academia and industry, providing entrepreneurs with access to a vast network of Silicon Valley leaders to facilitate rapid growth.
What's next for Deepcell?
With the recent influx of capital, Deepcell is poised to expand its service offerings and deepen its impact on the life sciences sector. The strategic focus will likely center on scaling the commercial availability of its platform for clinical and research partners, while further refining its AI algorithms to enhance classification accuracy. As the company moves into this next phase of growth, it is expected to play a pivotal role in the industrial renaissance of deep tech, bridging the gap between complex biological data and actionable medical insights. The continued support from top-tier investors signals a long-term commitment to fostering innovation in diagnostics and molecular information.
See full Deepcell company page
